Terramika Bellamy

发表

Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials

G. Kemble, C. Ambrose, Elissa M. Malkin, 2010, PloS one.

Safety and Immunogenicity Following Administration of a Live , Attenuated Monovalent 2009 H 1 N 1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials

G. Kemble, C. Ambrose, Elissa M. Malkin, 2010 .

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.

K. O'Brien, R. Karron, M. P. Griffin, 2015, The Lancet. Infectious diseases.

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.

H. Goossens, M. Bonten, H. Jafri, 2021, Lancet. Infectious Diseases (Print).

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

H. Goossens, B. Souweine, P. Póvoa, 2022, Critical Care.

Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study

H. Goossens, H. Jafri, J. Pugin, 2022, Journal of clinical microbiology.

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

H. Jafri, M. Esser, G. Robbie, 2016, Antimicrobial Agents and Chemotherapy.

Characterisation of anti‐alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin

D. Tabor, H. Jafri, M. Esser, 2018, Clinical & translational immunology.